Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)

Trial Profile

Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Teprotumumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors River Vision Development Corp
  • Most Recent Events

    • 17 Aug 2016 Status changed from recruiting to completed.
    • 04 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016, according to ClinicalTrials.gov record.
    • 04 Apr 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top